Health Economics›Pancreatic cancer›Metastatic disease gemcitabine-refractory

Metastatic disease gemcitabine-refractory

Pancreatic cancer · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
nab-Paclitaxel monotherapy Variant #01	—	R 45 710	28d	—	~11.1 mo	—	—	1
Capecitabine and Erlotinib Variant #01	—	R 11 417	21d	—	—	—	—	—
OLF Variant #01	—	R 5 928	56d	—	~7.5 mo	—	—	2
mFOLFIRINOX Variant #04	—	R 3 740	14d	~9.7 mo	~31.4 mo	~22	~R 82 287 PFS proxy · indirect	2
FOLFIRI Variant #05	—	R 2 826	14d	—	~6.7 mo	—	—	1
mFOLFOX6 Variant #02	—	R 2 466	14d	—	~6.3 mo	—	—	1
FOLFOX Variant #01	—	R 2 421	14d	—	—	—	—	—
CapeOx Variant #01	—	R 2 384	21d	~6.7 mo	~12.2 mo	~10	~R 23 842 PFS proxy · indirect	20
FULV and nanoliposomal Irinotecan Variant #01 Partial	—	R 1 617	14d	—	~6.7 mo	—	—	3
FULV Variant #01	—	R 1 466	35d	~2.9 mo	~20.1 mo	~3	~R 4 398 PFS proxy · indirect	6
Irinotecan liposomal monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—
S-1 monotherapy Variant #01 Partial	—	—	21d	—	~7.9 mo	—	—	3

12 of 12 regimens shown